Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Stealth Biotherapeutics Corp Ads (MITO)

Stealth Biotherapeutics Corp Ads (MITO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 382,906
  • Shares Outstanding, K 35,030
  • Annual Sales, $ 0 K
  • Annual Income, $ -96,710 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 111.68

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.04
  • Number of Estimates 2
  • High Estimate -0.04
  • Low Estimate -0.04
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.50 +68.11%
on 11/11/19
12.56 -12.96%
on 12/02/19
+4.46 (+68.95%)
since 11/08/19
3-Month
4.97 +119.94%
on 09/27/19
12.56 -12.96%
on 12/02/19
+3.18 (+41.04%)
since 09/09/19

Most Recent Stories

More News
Alexion (ALXN) Up 10 % YTD on Soliris & Ultomiris Strength

Alexion's (ALXN) stock rises 10% in the year so far as Soliris maintains momentum and Ultomiris gains further traction.

AMGN : 232.82 (-0.41%)
ACHN : 6.21 (+0.65%)
ALXN : 112.48 (-1.24%)
MITO : 10.93 (-7.21%)
Alexion (ALXN) Beats on Q3 Earnings, Lifts 2019 Guidance

Alexion (ALXN) rides high on earnings and revenue beat in the third quarter of 2019. The company also raises 2019 guidance.

INCY : 94.79 (+0.33%)
ACHN : 6.21 (+0.65%)
ALXN : 112.48 (-1.24%)
MITO : 10.93 (-7.21%)
Company News For Oct 11, 2019

Companies in the news are: RARX, BBBY, PCG, MITO

PCG : 11.18 (+15.85%)
BBBY : 15.41 (+4.33%)
MITO : 10.93 (-7.21%)
RARX : 47.12 (+0.26%)
Alexion (ALXN) Collaborates With Stealth BioTherapeutics

Alexion (ALXN) teams up with Stealth BioTherapeutics for a late-stage therapy for mitochondrial diseases.

AMGN : 232.82 (-0.41%)
ALXN : 112.48 (-1.24%)
EIDX : 59.61 (-0.23%)
MITO : 10.93 (-7.21%)
Alexion and Stealth Announce Agreement for Option to Co-Develop and Commercialize Late-Stage Therapy for Mitochondrial Diseases

--- If option is exercised, Alexion & Stealth will co-develop and co-promote subcutaneous elamipretide in U.S. & Alexion will receive exclusive ex-U.S. license -

ALXN : 112.48 (-1.24%)
MITO : 10.93 (-7.21%)
Stealth BioTherapeutics Enters Oversold Territory

Stealth BioTherapeutics Corp (MITO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

MITO : 10.93 (-7.21%)
Stealth BioTherapeutics Sees Hammer Chart Pattern: Time to Buy?

Stealth BioTherapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

MITO : 10.93 (-7.21%)
Hercules Capital Reports First Quarter 2019 Financial Results

--Grew Debt Investment Portfolio by $160.5 Million, Leading to Record Total Debt Investments of $1.91 Billion, at Cost

WFC : 53.92 (-0.83%)
MITO : 10.93 (-7.21%)
XFOR : 12.01 (+12.24%)
PINS : 18.21 (-2.93%)
WMT : 119.36 (-0.35%)
HTGC : 14.27 (+0.42%)
HCXZ : 25.55 (+0.49%)
HCXY : 26.35 (+1.58%)
Hercules Capital Reports Record Fourth Quarter and Full-Year 2018 Financial Results

--Record FY2018 New Debt and Equity Commitments of $1.21 Billion, up 37.6% Year-over-Year

WFC : 53.92 (-0.83%)
EDGE : 0.50 (+11.42%)
WMT : 119.36 (-0.35%)
MITO : 10.93 (-7.21%)
HTGC : 14.27 (+0.42%)
HCXZ : 25.55 (+0.49%)
HCXY : 26.35 (+1.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade MITO with:

Business Summary

Stealth BioTherapeutics Corp is a biopharmaceutical company. It is engaged in developing therapies to treat the mitochondrial dysfunction associated with genetic mitochondrial diseases and many common age-related diseases. The company's product pipeline includes Elamipretide, SBT-20 and SBT-272 which...

See More

Key Turning Points

2nd Resistance Point 12.61
1st Resistance Point 11.77
Last Price 10.93
1st Support Level 10.31
2nd Support Level 9.69

See More

52-Week High 20.99
Fibonacci 61.8% 14.87
Fibonacci 50% 12.98
Fibonacci 38.2% 11.09
Last Price 10.93
52-Week Low 4.97

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar